Photo from wikipedia
Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies. Lipoprotein apheresis (LA) has long been a standard of… Click to show full abstract
Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies. Lipoprotein apheresis (LA) has long been a standard of care for patients with severe FH, but is invasive, expensive and time‐consuming for patients and their caregivers. Newer drug therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may reduce the need for LA.
Keywords:
lipoprotein apheresis;
familial hypercholesterolaemia;
pcsk9 inhibitors;
severe familial
Journal Title: Journal of Clinical Apheresis
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Apheresis
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!